Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women

Breast Cancer Research

Volumn 9, Issue 6, 2007, Pages

  Trabert, Britton ^a,b   Malone, Kathleen E ^a,b   Daling, Janet R ^a,b   Doody, David R ^a   Bernstein, Leslie ^c   Ursin, Giske ^c,d   Marchbanks, Polly A ^e   Strom, Brian L ^f   Humphrey, Mariela C ^a   Ostrander, Elaine A ^a,g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ENDODEOXYRIBONUCLEASE BSMI; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BODY MASS; BREAST CANCER; BSMI GENE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; GEOGRAPHY; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POLY(A) GENE; POPULATION RESEARCH; POSTMENOPAUSE; RACE DIFFERENCE; SAMPLING; SMOKING; VDR GENE; BREAST TUMOR; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POSTMENOPAUSE; RECEPTORS, CALCITRIOL; RISK ASSESSMENT; RISK FACTORS; SMOKING; UNITED STATES;

EID: 40349084042     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1833     Document Type: Article

References (37)

1. Colston KW, Hansen CM: Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002, 9: 45-59 10.1677/erc.0.0090045.
2. Welsh J, Wietzke JA, Zinser GM, Smyczek S, Romu S, Tribble E, Welsh JC, Byrne B, Narvaez CJ: Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol. 2002, 83: 85-92 10.1016/S0960-0760(02)00277-7.
3. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW: Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005, 41: 1164-1169 10.1016/j.ejca.2005.01.017.
4. John EM, Schwartz GG, Dreon DM, Koo J: Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 1999, 8: 399-406.
5. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007, 85: 1586-1591.
6. Freedman DM, Looker AC, Chang SC, Graubard BI: Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst. 2007, 99: 1594-1602 10.1093/jnci/djm204.
7. Buist DS, LaCroix AZ, Barlow WE, White E, Weiss NS: Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol. 2001, 54: 417-422 10.1016/S0895-4356(00)00301-2.
8. Nelson RL, Turyk M, Kim J, Persky V: Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort. BMC Cancer. 2002, 2: 22. 10.1186/1471-2407-2-22.
9. Newcomb PA, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, Willett WC, Stampfer MJ: Fracture history and risk of breast and endometrial cancer. Am J Epidemiol. 2001, 153: 1071-1078 10.1093/aje/153.11.1071.
10. Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW: Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer. 2001, 85: 171-175 10.1054/bjoc.2001.1864.
11. Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, Shi CY, Yu MC, Ross RK, Coetzee GA: Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomarkers Prev. 1997, 6: 93-98.
12. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997, 89: 166-170 10.1093/jnci/89.2.166.
13. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ: Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev. 1998, 7: 385-390.
14. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996, 56: 4108-4110.
15. Uitterlinden AG, Fang Y, van Meurs JB, Pols HA, van Leeuwen JP: Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004, 338: 143-156 10.1016/j.gene.2004.05.014.
16. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, Wilson RG, Thomas V, Colston KW: Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004, 10: 5472-5481 10.1158/1078-0432.CCR-04-0206.
17. Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, Haile RW, Coetzee GA: Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control. 2000, 11: 25-30 10.1023/A:1008979417618.
18. Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE: Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2335-2339 10.1158/1055-9965.EPI-05-0283.
19. Ruggiero M, Pacini S, Aterini S, Fallai C, Ruggiero C, Pacini P: Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res. 1998, 10: 43-46.
20. Buyru N, Tezol A, Yosunkaya-Fenerci E, Dalay N: Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med. 2003, 35: 550-555.
21. Cooper GS, Umbach DM: Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res. 1996, 11: 1841-1849.
22. Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J: Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 2004, 19: 419-428 10.1359/JBMR.0301265.
23. Marchbanks PA, Mcdonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, et al: The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol. 2002, 12: 213-221 10.1016/S1047-2797(01)00274-5.
24. Sambrook JFEMT: Isolation of high-molecular weight DNA from mammalian cells. Molecular Cloning: A Laboratory Manual. Edited by: Nolan C. 1989, Plainview, NY: Cold Spring Harbor Press, 16-19.
25. Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA: Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate. 2004, 59: 409-418 10.1002/pros.20001.
26. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, et al: Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years. Cancer Res. 2006, 66: 8297-8308 10.1158/0008-5472.CAN-06-0503.
27. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, et al: Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol. 2002, 100: 1148-1158 10.1016/S0029-7844(02)02502-4.
28. McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, Thun MJ, Calle EE: Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007, 9: R9. 10.1186/bcr1642.
29. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Coates RJ, Liff JM, Talamini R, Chantarakul N, et al: Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002, 87: 1234-1245 10.1038/sj.bjc.6600596.
30. Saintot M, Malaveille C, Hautefeuille A, Gerber M: Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk. Int J Cancer. 2003, 107: 652-657 10.1002/ijc.11432.
31. Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA: Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat. 2005, 93: 261-270 10.1007/s10549-005-5347-8.
32. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A: Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control. 1998, 9: 559-566 10.1023/A:1008823601897.
33. 2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control. 1998, 9: 567-582 10.1023/A:1008835903714.
34. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC: Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst. 2002, 94: 1301-1311.
35. Liu Z, Calderon JI, Zhang Z, Sturgis EM, Spitz MR, Wei Q: Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer. Pharmacogenet Genomics. 2005, 15: 159-165.
36. Daniell HW: Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology. 2001, 58: 101-107 10.1016/S0090-4295(01)01251-1.
37. Smith MR: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002, 60: 79-85 10.1016/S0090-4295(02)01579-0.